Celcuity Osake

Celcuity EV/FCF

EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä Celcuity (CELC) 23.7.2026 päivämäärällä on −60,81. Edellisenä vuonna EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) oli −94,32 — muutos −35,53 % (korkeampi).

EV/FCF

−60,81

YoY

−35,53%

Viimeksi päivitetty:

EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä Celcuity on 2026 −60,81 . EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä Celcuity oli 2025 −94,32 . Se laskee −35,53% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Celcuity Osakeanalyysi

Mitä Celcuity tekee? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Celcuity osakkeesta

Yhtiön Celcuity EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) on −60,81 vuonna 2026.

Access this data via the Eulerpool API

Arvostus — Celcuity

Kaikki tunnusluvut — Celcuity